Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Aerosol therapy]

J H Wildhaber1

  • 1Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Australia. hannesw@cyllene.uwa.edu.au

Schweizerische Medizinische Wochenschrift
|October 3, 1998
PubMed
Summary
This summary is machine-generated.

Efficient aerosol therapy for lung diseases requires optimal inhalation devices. Newer devices and techniques significantly improve drug delivery to the airways, enhancing treatment effectiveness and patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exhaled nitric oxide in symptomatic children at preschool age predicts later asthma.

Allergy·2013
Same author

[Intermittent or persistent rhinitis in children and adolescents with Asthma: «the Swiss LARA paediatrics survey»].

Praxis·2011
Same author

Predictors of asthma control in everyday clinical practice in Switzerland.

Current medical research and opinion·2009
Same author

Paediatric HERMES: update of the European Training Syllabus for Paediatric Respiratory Medicine.

The European respiratory journal·2009
Same author

Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach.

The European respiratory journal·2008
Same author

Longitudinal monitoring of pediatric cystic fibrosis lung disease using nitrite in exhaled breath condensate.

Pediatric pulmonology·2007
Same journal

Respiratory function test in the case of temporary phrenic nerve contusion, associated with pneumoperitoneum; About the diagnostic value of laparoscopy.

Schweizerische medizinische Wochenschrift·2010
Same journal

Treatment of pulmonary tuberculosis and pleurisy by means of temporary paralysis of the diaphragm, supported by the pneumoperitoneum.

Schweizerische medizinische Wochenschrift·2010
Same journal

Boeck's disease as a tuberculous syndrome.

Schweizerische medizinische Wochenschrift·2010
Same journal

Enteral primary tubercular complexes

Schweizerische medizinische Wochenschrift·2010
Same journal

Tuberculous stenoses of the large bronchi.

Schweizerische medizinische Wochenschrift·2010
Same journal

About the enzyme action.

Schweizerische medizinische Wochenschrift·2010
See all related articles

Area of Science:

  • Respiratory medicine
  • Pharmaceutical technology
  • Medical device engineering

Context:

  • Aerosol therapy is crucial for diagnosing and treating lung diseases.
  • Effective inhalation therapy aims for reproducible drug deposition in airways, maximizing local effects and minimizing systemic side effects.
  • Current inhalation devices (nebulizers, metered-dose inhalers, dry powder inhalers) have limitations in aerosol delivery efficiency.

Purpose:

  • To review the efficiency of various inhalation devices for aerosol drug delivery.
  • To highlight advancements in inhalation device technology and their impact on lung deposition.
  • To emphasize the importance of device selection based on aerosol characteristics, patient factors, and clinical outcomes.

Summary:

  • Radiolabeled deposition studies indicate suboptimal lung delivery with traditional nebulizers and metered-dose inhalers (MDIs), with pre-1997 lung deposition ranging from 0.5%–15% in children and 30% in adults.

Related Experiment Videos

  • Dry powder inhalers (DPIs) were more efficient pre-1997, achieving 30% lung deposition in adults and children.
  • Post-1997 advancements, including the use of holding chambers and hydrofluoroalkane (HFA) propellants in MDIs, have significantly improved lung deposition, reaching up to 60%.

    • Impact:

    • The choice of inhalation device is critical for clinical efficacy, influenced by aerosol properties, patient ventilation, airway morphology, and device acceptance.
    • Development of more efficient, user-friendly, portable, and versatile inhalation devices is essential for diverse patient populations and medications.
    • Future devices must be cost-effective, environmentally safe, and rigorously assessed for different age groups to optimize aerosol therapy outcomes.